High Frequency of Bone/Bone Marrow Involvement in Advanced Medullary Thyroid Cancer
E. Mirallié,
J. P. Vuillez,
S. Bardet,
E. Frampas,
B. Dupas,
L. Ferrer,
A. Faivre-Chauvet,
A. Murat,
B. Charbonnel,
J. Barbet,
D. M. Goldenberg,
J. F. Chatal and
F. Kraeber-Bodéré
Oncology Research Department (E.M., A.F.-C., J.B., J.F.C., F.K.-B.), Inserm U601, 44093 Nantes, France; Nuclear Medicine Department (J.P.V.), University Hospital, 38043 Grenoble, France; Nuclear Medicine Department (S.B.), François Baclesse Cancer Center, 14021 Caen, France; Radiology (E.F., B.D.) and Endocrinology (B.C., A.M.) Departments, University Hospital, 44093 Nantes, France; Nuclear Medicine Department (L.F.), René Gauducheau Cancer Center, 44805 Nantes, France; and Garden State Cancer Center (D.M.G.), Center for Molecular Medicine and Immunology, Belleville, New Jersey 07109-0023
Address all correspondence and requests for reprints to: Françoise Kraeber-Bodéré, Oncology Research Department, Inserm U601, Institut de Biologie, 9 quai Moncousu, 44093 Nantes Cedex 1, France. E-mail: francoise.bodere{at}chu-nantes.fr.
High hematological toxicity has been observed with anti-carcinoembryonicantigen radioimmunotherapy (RIT) in medullary thyroid carcinoma(MTC), suggesting metastatic bone involvement (BI). This retrospectivestudy evaluated the rate of BI in MTC patients enrolled in twophase-I/II RIT trials using anti-carcinoembryonic antigen xanti-diethylenetriamine pentaacetic acid bispecific antibodiesand [131I]di-diethylenetriamine pentaacetic acid hapten. Thirty-fivepatients underwent bone scintigraphy, bone magnetic resonanceimaging (MRI), and post-RIT immunoscintigraphy (IS). IS performedin MTC patients was compared with IS conducted in 12 metastaticcolorectal carcinoma (CRC) patients. Quantitative analysis ofbone uptake was performed in three MTC and three CRC patients.In the MTC group, bone scintigraphy detected BI in 56.6% ofpatients, MRI in 75.8%, and IS in 88.6%. BI was confirmed byundirected (random) bone marrow biopsy, by bone surgery, orby two positive imaging methods in 74.3% of the patients. Sensitivityper patient of bone scintigraphy, MRI, and IS were 72.7, 100,and 100%, respectively. In contrast, IS visualized BI in only33.3% of CRC patients; bone uptake was lower in CRC than inMTC patients. Bone MRI combined with post-RIT IS disclosed amuch higher BI rate in advanced MTC than previously reportedin the literature.
This article has been cited by other articles:
D. M. Goldenberg, E. A. Rossi, R. M. Sharkey, W. J. McBride, and C.-H. Chang Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting
J. Nucl. Med.,
January 1, 2008;
49(1):
158 - 163.
[Abstract][Full Text][PDF]
A. Oudoux, P.-Y. Salaun, C. Bournaud, L. Campion, C. Ansquer, C. Rousseau, S. Bardet, F. Borson-Chazot, J.-P. Vuillez, A. Murat, et al. Sensitivity and Prognostic Value of Positron Emission Tomography with F-18-Fluorodeoxyglucose and Sensitivity of Immunoscintigraphy in Patients with Medullary Thyroid Carcinoma Treated with Anticarcinoembryonic Antigen-Targeted Radioimmunotherapy
J. Clin. Endocrinol. Metab.,
December 1, 2007;
92(12):
4590 - 4597.
[Abstract][Full Text][PDF]
A. L. Giraudet, D. Vanel, S. Leboulleux, A. Auperin, C. Dromain, L. Chami, N. Ny Tovo, J. Lumbroso, N. Lassau, G. Bonniaud, et al. Imaging Medullary Thyroid Carcinoma with Persistent Elevated Calcitonin Levels
J. Clin. Endocrinol. Metab.,
November 1, 2007;
92(11):
4185 - 4190.
[Abstract][Full Text][PDF]
J.-F. Chatal, L. Campion, F. Kraeber-Bodere, S. Bardet, J.-P. Vuillez, B. Charbonnel, V. Rohmer, C.-H. Chang, R. M. Sharkey, D. M. Goldenberg, et al. Survival Improvement in Patients With Medullary Thyroid Carcinoma Who Undergo Pretargeted Anti-Carcinoembryonic-Antigen Radioimmunotherapy: A Collaborative Study With the French Endocrine Tumor Group
J. Clin. Oncol.,
April 10, 2006;
24(11):
1705 - 1711.
[Abstract][Full Text][PDF]
D. M. Goldenberg, R. M. Sharkey, G. Paganelli, J. Barbet, and J.-F. Chatal Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy
J. Clin. Oncol.,
February 10, 2006;
24(5):
823 - 834.
[Abstract][Full Text][PDF]
R. M. Reilly Radioimmunotherapy of Solid Tumors: The Promise of Pretargeting Strategies Using Bispecific Antibodies and Radiolabeled Haptens
J. Nucl. Med.,
February 1, 2006;
47(2):
196 - 199.
[Full Text][PDF]
F. Kraeber-Bodere, C. Rousseau, C. Bodet-Milin, L. Ferrer, A. Faivre-Chauvet, L. Campion, J.-P. Vuillez, A. Devillers, C.-H. Chang, D. M. Goldenberg, et al. Targeting, Toxicity, and Efficacy of 2-Step, Pretargeted Radioimmunotherapy Using a Chimeric Bispecific Antibody and 131I-Labeled Bivalent Hapten in a Phase I Optimization Clinical Trial
J. Nucl. Med.,
February 1, 2006;
47(2):
247 - 255.
[Abstract][Full Text][PDF]
M. G. E. H. Lam, C. J. M. Lips, P. L. Jager, R. P. F. Dullaart, E. G. W. M. Lentjes, P. P. van Rijk, and J. M. H. de Klerk Repeated [131I]Metaiodobenzylguanidine Therapy in Two Patients with Malignant Pheochromocytoma
J. Clin. Endocrinol. Metab.,
October 1, 2005;
90(10):
5888 - 5895.
[Abstract][Full Text][PDF]
R. M. Sharkey, H. Karacay, T. M. Cardillo, C.-H. Chang, W. J. McBride, E. A. Rossi, I. D. Horak, and D. M. Goldenberg Improving the Delivery of Radionuclides for Imaging and Therapy of Cancer Using Pretargeting Methods
Clin. Cancer Res.,
October 1, 2005;
11(19):
7109s - 7121s.
[Abstract][Full Text][PDF]
R. M. Sharkey, G. Hajjar, D. Yeldell, A. Brenner, J. Burton, A. Rubin, and D. M. Goldenberg A Phase I Trial Combining High-Dose 90Y-Labeled Humanized Anti-CEA Monoclonal Antibody with Doxorubicin and Peripheral Blood Stem Cell Rescue in Advanced Medullary Thyroid Cancer
J. Nucl. Med.,
April 1, 2005;
46(4):
620 - 633.
[Abstract][Full Text][PDF]
A. Machens, U. Schneyer, H.-J. Holzhausen, and H. Dralle Prospects of Remission in Medullary Thyroid Carcinoma According to Basal Calcitonin Level
J. Clin. Endocrinol. Metab.,
April 1, 2005;
90(4):
2029 - 2034.
[Abstract][Full Text][PDF]
